{"id":"W7108479951","doi":"10.1182/blood-2025-484","title":"Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Anemia; Phases of clinical research; Monoclonal; Thrombopoietin; Clinical endpoint; Essential thrombocythemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001093967,0.0005744293,0.001480108,0.0002640578,0.000212061,0.0008149046,0.0004786986,0.0006934233,0.001641116],"category_scores_gemma":[0.0008143786,0.0002585597,0.001095219,0.000362868,0.0003454595,0.0005715003,0.000226263,0.001575208,0.0004796121],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007962453,"about_ca_system_score_gemma":0.0005531009,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004767294,"about_ca_topic_score_gemma":0.001432815,"domain_scores_codex":[0.9996648,0.0001376033,0.00003347866,0.0000639034,0.00005029439,0.00004994451],"domain_scores_gemma":[0.9994548,0.0001208646,0.0001951822,0.00003504677,0.00004010716,0.000154021],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4564787,0.01505016,0.0348099,0.001585545,0.003368431,0.000457267,0.0003689511,0.005366334,0.09850214,0.0002915439,0.006410275,0.3773107],"study_design_scores_gemma":[0.2370249,0.5836634,0.1356753,0.0002256996,0.003418774,0.002336943,0.0001960104,0.00465329,0.0193791,0.0005158767,0.01281206,0.0000986968],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9903674,0.005854066,0.0003959029,0.0004054759,0.00005013445,0.0003700524,0.0010555,0.00006410447,0.001437324],"genre_scores_gemma":[0.9959549,0.001637263,0.0004479478,0.0003083152,0.00005022481,0.0002190945,0.0008206153,0.00001438599,0.0005471556],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001641116,"threshold_uncertainty_score":0.005785525,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01524992112569751,"score_gpt":0.3173373087987922,"score_spread":0.3020873876730947,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}